Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Romanowski

Showing results (81-90 of 86) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 86 results.
Vaccine|October 16, 2012
Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult womenA-B Moscicki, C M Wheeler, B Romanowski, et al.
Chemical Science|September 23, 2024
Discovery of megapolipeptins by genome mining of a <i>Burkholderiales</i> bacteria collectionBruno S Paulo, Michael J J Recchia, Sanghoon Lee, et al.
Lancet (London, England)|July 10, 2009
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young womenJ Paavonen, P Naud, J Salmerón, et al.
Vaccine|July 16, 2013
Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial, R R Abu-Elyazeed, T Heineman, et al.
International Journal of Cancer|August 23, 2011
Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18A Szarewski, W A J Poppe, S R Skinner, et al.
Lancet (London, England)|December 8, 2009
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years, B Romanowski, P Colares de Borba, et al.
Pageof 9

Showing results (81-90 of 86) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 86 results.
Vaccine|October 16, 2012
Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult womenA-B Moscicki, C M Wheeler, B Romanowski, et al.
Chemical Science|September 23, 2024
Discovery of megapolipeptins by genome mining of a <i>Burkholderiales</i> bacteria collectionBruno S Paulo, Michael J J Recchia, Sanghoon Lee, et al.
Lancet (London, England)|July 10, 2009
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young womenJ Paavonen, P Naud, J Salmerón, et al.
Vaccine|July 16, 2013
Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial, R R Abu-Elyazeed, T Heineman, et al.
International Journal of Cancer|August 23, 2011
Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18A Szarewski, W A J Poppe, S R Skinner, et al.
Lancet (London, England)|December 8, 2009
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years, B Romanowski, P Colares de Borba, et al.
Pageof 9